Age, sex, performance status, planned chemotherapy, prior adjuvant chemotherapy, assigned treatment arm, KRAS status, tumor sidedness, plasma albumin, diabetes, BMI, and fasting status. This evidence concerns the gene KRAS and neoplasm.